Stockreport

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]

Orchestra BioMed Holdings, Inc. - Ordinary Shares  (OBIO) 
PDF Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics' Vivasure acquisition proceeds $33.5 million in 2025 non-recurring reven [Read more]